Details of the Drug

General Information of Drug (ID: DMFJZN0)

Drug Name
Romosozumab
Synonyms AMG 785
Indication
Disease Entry ICD 11 Status REF
Postmenopausal osteoporosis FB83.11 Approved [1]
Affected Organisms
Humans and other mammals
ATC Code
M05BX06: Romosozumab
M05BX: Other drugs affecting bone structure and mineralization
M05B: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION
M05: DRUGS FOR TREATMENT OF BONE DISEASES
M: MUSCULO-SKELETAL SYSTEM
Drug Type
Antibody
ADMET Property
Clearance
The clearance of drug is 0.38 mL/h/kg [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 12.8 days [2]
Vd
The volume of distribution (Vd) of drug is 3.92 L [2]
Cross-matching ID
UNII
3VHF2ZD92J
DrugBank ID
DB11866
TTD ID
D0K3LO

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Sclerostin (SOST) TTYRO4F SOST_HUMAN Not Available [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Postmenopausal osteoporosis
ICD Disease Classification FB83.11
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Sclerostin (SOST) DTT SOST 1.11E-01 0.9 2.87
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Romosozumab (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Etelcalcetide DMHP9BL Major Increased risk of hypocalcemia by the combination of Romosozumab and Etelcalcetide. Hyper-parathyroidism [5A51] [3]

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
2 FDA Approved Drug Products: EVENITY (romosozumab-aqqg) injection, for subcutaneous use
3 Cerner Multum, Inc. "UK Summary of Product Characteristics.".